Antibiotic clarithromycin market grows fourfold in 3 yrs
By Chon, Seung-Hyun | translator Hong, Ji Yeon
24.12.10 05:45:33
가나다라
0
Outpatient prescription sales of clarithromycin have increased by 46% in Q3 YoY
A four-fold expansion from Q3 2021…issues with impurity-related risk occurred in 2022
A significant increase in usage following the endemic period..exceeded the first KRW 100B mark in prescription sales last year
The prescription market for the antibiotic clarithromycin has significantly expanded. The market size grew by nearly fourfold over three years. Impurities-related cautions were once issued, but the volume of use increased during the COVID-19 pandemic and endemic period.
According to a pharmaceutical market research firm UBIST on December 9, the outpatient prescription market for clarithromycin in Q3 amounted to KRW 35.6 billion, up 45.6%. The macrolide antibiotic clarithromycin is a medicine used to treat respiratory infections, pneumonia, pharyngitis, tonsillitis, and sinusitis.
▲Quarterly outpatient prescription sales for clarithromycin (unit: KRW 100 million, source: UBIST).
The prescription market for clarithromycin has significantly increased throughout the pandemic and en
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)